2019 DNA Immune Response Virus 
PLOS: DNA Science
OCTOBER 12, 2023
Can they deliver healing genes without triggering an overactive immune response? The details are disturbingly reminiscent of the famous case of Jesse Gelsinger , who died from a ferocious immune response to experimental gene therapy in September 1999. million DNA bases. Affected children rarely live past infancy.
Drug Target Review
OCTOBER 26, 2023
Genome engineering and gene therapies that manipulate DNA sequences in cells have driven a biotechnological revolution over the past decade. 1 Adeno-associated virus (AAV) vectors are the leading platform for in vivo gene delivery for the treatment of various human diseases. Nature reviews Drug discovery 18 , 358-378 (2019).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PLOS: DNA Science
MAY 16, 2024
Many of the links below are to some of the 100+ DNA Science posts that I wrote during the pandemic. A Novel Virus Appears In retrospect, everything unfolded with astonishing speed. ” I’ve long thought that SARS-CoV-2, or an immediate viral predecessor, emerged years before 2019 – at least as far back as 2013.
The Pharma Data
NOVEMBER 29, 2020
Compared to placebo, participants vaccinated with three HB-101 doses had: a 48 percent reduction in CMV viremia (presence of CMV DNA in the blood); a 42 percent reduction in the use of antiviral therapy; and. 3 The majority of CMV infections are not serious, and the virus can lay dormant in the body for years.
Codon
JULY 27, 2023
They’ve just finished sequencing the patient’s genome, but they don’t have “DNA sorting” software. billion units of DNA code are transcribed into more than a hundred volumes, each a thousand pages long, in type so small as to be barely legible.” a lower risk of immune responses.
Codon
JULY 27, 2023
They’ve just finished sequencing the patient’s genome, but they don’t have “DNA sorting” software. billion units of DNA code are transcribed into more than a hundred volumes, each a thousand pages long, in type so small as to be barely legible.” a lower risk of immune responses.
Drug Discovery World
FEBRUARY 2, 2023
The lead AdAPT candidate, AdAPT-001, in a Phase I/II clinical trial for the treatment of cancer, carries an extra piece of DNA called a transgene that binds to, traps, and neutralises a molecule called transforming growth factor-beta (TGF-b), which tumours hijack to suppress the antitumour immune response. Future Oncol.
Expert insights. Personalized for you.
69 
Let's personalize your content